ArticleFrontiers in oncology2025
Establishment of a novel renal immune prognostic index to predict clinical outcomes in renal cell cancer patients who received surgery.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study is to establish a novel Renal Immune Prognostic Index (RIPI) and investigate its predictive ability for the clinical outcomes of renal cell cancer (RCC) patients. Methods: This multicenter retrospective study included 259 RCC patients who underwent surgical resection at the Second Affiliated Hospital of Harbin Medical University (January 2016-December 2017) as the training cohort, and 350 patients from Harbin Medical University Cancer Hospital during the same period as the external validation cohort. The RIPI was developed using Cox regression with multicollinearity addressed by Lasso regression. The optimal cutoff was determined by Receiver Operating Characteristic (ROC) curve analysis. Survival differences were evaluated with Kaplan-Meier curves, and potential confounding factors were adjusted using Propensity Score Matching (PSM). Model performance and clinical utility were assessed using the concordance index (C-index), calibration curves, time-dependent ROC curves, and decision curve analysis (DCA). Results: Lasso regression identified prealbumin (PALB), lymphocyte count (LYM), and immunoglobulin M (IgM) as key hematological prognostic parameters. RIPI was constructed as: RIPI = 0.005 × PALB (g/L) + 0.248 × LYM (10 Conclusion: This multicenter retrospective study demonstrated that RIPI, integrating PALB, LYM, and IgM, provides robust and reproducible prognostic value in RCC patients. RIPI represents a reliable and clinically applicable tool for individualized risk stratification and outcome prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.